Payment overview · 2025
General Payments
$351.87
24 reported records · 11 companies
Healthcare provider profile · identity verified
Veryl D Hodges, DO
Allopathic & Osteopathic Physicians|Internal Medicine · JONESBORO, AR · NPI 1013903269
Verified facts
What the public records show
CMS Open Payments records show Veryl D Hodges, DO received $351.87 in general payments during 2025 across 24 reported records.
ABBVIE INC. accounted for 39.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $139.70 | 39.7% | 12 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $38.00 | 10.8% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $34.14 | 9.7% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $24.82 | 7.0% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $23.33 | 6.6% | 1 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $20.18 | 5.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $19.08 | 5.4% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $15.37 | 4.4% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $15.17 | 4.3% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $14.26 | 4.0% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $7.82 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $351.87 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $119.97 | 10 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $101.50 | 8 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $38.00 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $34.14 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $24.82 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $24.82 | 1 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $23.33 | 1 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $20.18 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $19.73 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $19.08 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $15.37 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $15.17 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $15.17 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $14.26 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $7.82 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
118 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 472 | 124 |
| Levothyroxine Sodium | Levothyroxine Sodium | 420 | 97 |
| Pantoprazole Sodium | Pantoprazole Sodium | 325 | 83 |
| Alprazolam | Alprazolam | 291 | 63 |
| Omeprazole | Omeprazole | 290 | 65 |
| Losartan Potassium | Losartan Potassium | 268 | 67 |
| Amlodipine Besylate | Amlodipine Besylate | 261 | 79 |
| Gabapentin | Gabapentin | 249 | 65 |
| Tamsulosin Hcl | Tamsulosin Hcl | 247 | 57 |
| Lisinopril | Lisinopril | 239 | 59 |
| Furosemide | Furosemide | 224 | 59 |
| Pioglitazone Hcl | Pioglitazone Hcl | 202 | 45 |
| Duloxetine Hcl | Duloxetine Hcl | 172 | 43 |
| Potassium Chloride | Potassium Chloride | 149 | 40 |
| Metformin Hcl | Metformin Hcl | 147 | 38 |
| Spironolactone | Spironolactone | 137 | 34 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 135 | 29 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 134 | 33 |
| Simvastatin | Simvastatin | 132 | 31 |
| Meloxicam | Meloxicam | 131 | 33 |
| Trazodone Hcl | Trazodone Hcl | 130 | 36 |
| Clonazepam | Clonazepam | 119 | 21 |
| Eliquis | Apixaban | 118 | 22 |
| Carvedilol | Carvedilol | 117 | 29 |
| Tramadol Hcl | Tramadol Hcl | 117 | 32 |
| Zolpidem Tartrate | Zolpidem Tartrate | 113 | 18 |
| Donepezil Hcl | Donepezil Hcl | 112 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 106 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 105 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 101 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 100 | 28 |
| Allopurinol | Allopurinol | 97 | 25 |
| Ezetimibe | Ezetimibe | 97 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 97 | 20 |
| Bupropion Xl | Bupropion Hcl | 92 | 31 |
| Montelukast Sodium | Montelukast Sodium | 91 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 86 | 22 |
| Sertraline Hcl | Sertraline Hcl | 78 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 77 | 21 |
| Lorazepam | Lorazepam | 74 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 73 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 70 | 20 |
| Temazepam | Temazepam | 68 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 64 | 14 |
| Famotidine | Famotidine | 63 | 20 |
| Pregabalin | Pregabalin | 63 | 11 |
| Glimepiride | Glimepiride | 58 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 56 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 54 | 15 |
| Ozempic | Semaglutide | 52 | suppressed |
| Xarelto | Rivaroxaban | 52 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 50 | 14 |
| Topiramate | Topiramate | 49 | suppressed |
| Diazepam | Diazepam | 47 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 47 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 47 | suppressed |
| Ondansetron Odt | Ondansetron | 47 | 15 |
| Warfarin Sodium | Warfarin Sodium | 45 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 43 | 28 |
| Baclofen | Baclofen | 42 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 42 | 13 |
| Jardiance | Empagliflozin | 41 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 41 | suppressed |
| Estradiol | Estradiol | 40 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 39 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 39 | 12 |
| Alendronate Sodium | Alendronate Sodium | 38 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | 11 |
| Fenofibrate | Fenofibrate | 37 | suppressed |
| Linzess | Linaclotide | 37 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 35 | suppressed |
| Finasteride | Finasteride | 35 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 35 | 11 |
| Valsartan | Valsartan | 35 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 34 | suppressed |
| Azithromycin | Azithromycin | 33 | 32 |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 31 | suppressed |
| Glipizide | Glipizide | 31 | suppressed |
| Januvia | Sitagliptin Phosphate | 30 | suppressed |
| Lovastatin | Lovastatin | 30 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 30 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Memantine Hcl | Memantine Hcl | 28 | suppressed |
| Nifedipine Er | Nifedipine | 28 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 28 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | suppressed |
| Cephalexin | Cephalexin | 26 | 21 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 26 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Dexamethasone | Dexamethasone | 25 | 23 |
| Digoxin | Digoxin | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 11 |
| Atenolol | Atenolol | 24 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 22 | suppressed |
| Lansoprazole | Lansoprazole | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | suppressed |
| Methylprednisolone | Methylprednisolone | 22 | 21 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 15 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 20 | suppressed |
| Fluconazole | Fluconazole | 20 | 14 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 20 | 17 |
| Metformin Hcl Er | Metformin Hcl | 20 | suppressed |
| Mounjaro | Tirzepatide | 20 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 18 | 11 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 18 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Prednisone | Prednisone | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Roflumilast | Roflumilast | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Nabumetone | Nabumetone | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $351.87 · 24 records | ABBVIE INC. | Arikayce, BREZTRI, CAPVAXIVE, Cologuard Collection Kit, GARDASIL 9, GEMTESA, NURTEC ODT, QULIPTA, REXULTI, SKYCLARYS, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error